MA39450B2 - Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine - Google Patents

Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Info

Publication number
MA39450B2
MA39450B2 MA39450A MA39450A MA39450B2 MA 39450 B2 MA39450 B2 MA 39450B2 MA 39450 A MA39450 A MA 39450A MA 39450 A MA39450 A MA 39450A MA 39450 B2 MA39450 B2 MA 39450B2
Authority
MA
Morocco
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
enantiomers
medicine
Prior art date
Application number
MA39450A
Other languages
English (en)
Other versions
MA39450A1 (fr
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Ramos Damil
Oliveira Santos Pedro Paulo De Lacerda E
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA39450A1 publication Critical patent/MA39450A1/fr
Publication of MA39450B2 publication Critical patent/MA39450B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des sels pharmaceutiquement acceptables de composés de (r)-pirlindole et de (s)-pirlindole énantiomériquement purs, qui présentent un profil de biodisponibilité acrrue et se destinent à un usage médical.
MA39450A 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine MA39450B2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (fr) 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Publications (2)

Publication Number Publication Date
MA39450A1 MA39450A1 (fr) 2017-08-31
MA39450B2 true MA39450B2 (fr) 2021-10-29

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39450A MA39450B2 (fr) 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Country Status (18)

Country Link
US (1) US10226460B2 (fr)
EP (2) EP3831385B1 (fr)
JP (1) JP6400121B2 (fr)
KR (1) KR102276281B1 (fr)
CN (1) CN106413713B (fr)
AU (1) AU2014393487B2 (fr)
CA (1) CA2948595C (fr)
EC (1) ECSP16086196A (fr)
IL (1) IL248852B (fr)
MA (1) MA39450B2 (fr)
MX (1) MX2016014704A (fr)
NZ (1) NZ726127A (fr)
PH (1) PH12016502235A1 (fr)
RU (1) RU2706688C2 (fr)
SA (1) SA516380258B1 (fr)
TN (1) TN2016000495A1 (fr)
UA (1) UA118587C2 (fr)
WO (1) WO2015171002A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116499C2 (uk) * 2014-05-09 2018-03-26 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
LT3057589T (lt) * 2014-05-09 2017-11-27 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (s)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje
EP3392250A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
EP3392251A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170473B1 (da) * 1985-06-20 1995-09-11 Daiichi Seiyaku Co S(-)-pyridobenzoxazinforbindelser
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
EP1688161A1 (fr) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
WO2014062621A1 (fr) * 2012-10-15 2014-04-24 Stc.Unm Traitement de troubles basés sur l'autophagie et compositions pharmaceutiques, tests et kits de diagnostic et de dépistage associés
CA2948604C (fr) * 2014-05-09 2021-06-15 Tecnimede Sociedade Tecnico-Medicinal S.A. Procede d'obtention d'enantiomeres de pirlindole optiquement actifs et de sels de ceux-ci
UA116499C2 (uk) * 2014-05-09 2018-03-26 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
LT3057589T (lt) * 2014-05-09 2017-11-27 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (s)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje

Also Published As

Publication number Publication date
US20170143710A1 (en) 2017-05-25
KR102276281B1 (ko) 2021-07-13
TN2016000495A1 (en) 2018-04-04
JP6400121B2 (ja) 2018-10-03
CN106413713A (zh) 2017-02-15
AU2014393487A1 (en) 2016-11-24
SA516380258B1 (ar) 2019-11-04
MX2016014704A (es) 2017-05-23
IL248852B (en) 2020-05-31
IL248852A0 (en) 2017-01-31
NZ726127A (en) 2019-03-29
ECSP16086196A (es) 2017-02-24
EP3831385B1 (fr) 2024-07-10
CA2948595C (fr) 2021-07-13
WO2015171002A1 (fr) 2015-11-12
UA118587C2 (uk) 2019-02-11
CN106413713B (zh) 2020-07-14
RU2706688C2 (ru) 2019-11-20
MA39450A1 (fr) 2017-08-31
PH12016502235A1 (en) 2017-01-09
CA2948595A1 (fr) 2015-11-12
AU2014393487B2 (en) 2020-01-02
RU2016148174A3 (fr) 2018-06-14
EP3139926A1 (fr) 2017-03-15
EP3831385A1 (fr) 2021-06-09
KR20170002433A (ko) 2017-01-06
JP2017514882A (ja) 2017-06-08
US10226460B2 (en) 2019-03-12
RU2016148174A (ru) 2018-06-14

Similar Documents

Publication Publication Date Title
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201790271A1 (ru) Ингибиторы гликозидазы
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
EP3970712A3 (fr) Formes posologiques solides orales de 2r, 6r-hydroxynorkétamine ou leurs dérivés
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
MX2017016802A (es) Formulaciones farmaceuticas.
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
SV2016005313A (es) Derivados de carboxamida
EP3405211A4 (fr) Octréotide par voie orale pour le traitement de maladies
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
MA39450B2 (fr) Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
GB2501050A (en) Pharmaceutical compositons of immunosuppressants
EA201991141A1 (ru) Усилители bmp
TH1601007484A (th) สารประกอบเฮเทอโรแอริลสำหรับการยับยั้งไคเนส
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом